1061314-02-0

Basic information

• Product Name: 2-bromo-5-chloro-4-methyl-benzoic acid methyl ester
• Synonyms: 2-bromo-5-chloro-4-methyl-benzoic acid methyl ester
• CAS NO: 1061314-02-0
• Molecular Weight: 263.518
• Mol File: 1061314-02-0.mol

Chemical Properties

• Boiling Point: 300.0±37.0 °C(Predicted)
• Density: 1.534±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-bromo-5-chloro-4-methyl-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-5-chloro-4-methyl-benzoic acid methyl ester(1061314-02-0)
• EPA Substance Registry System: 2-bromo-5-chloro-4-methyl-benzoic acid methyl ester(1061314-02-0)

Safety Data

• Hazardous Substances Data: 1061314-02-0(Hazardous Substances Data)

Upstream product

• 7697-27-0 2-bromo-4-methylbenzoic acid 
• 67-56-1 methanol 
• 1426923-27-4 C₈H₆BrClO₂ 
• 745048-63-9 5-amino-2-bromo-4-methylbenzoic acid 
• 2458-12-0 3-amino-p-toluic acid 
• 474330-54-6 5-amino-2-bromo-4-methylbenzoic acid methyl ester 

Downstream Products

• 1061314-04-2 5-bromo-2-chloro-4-(methoxycarbonyl)benzoic acid 
• 1313513-41-5 methyl 2-bromo-4-(bromomethyl)-5-chlorobenzoate 
• 1313513-42-6 methyl 4-(acetoxymethyl)-2-bromo-5-chlorobenzoate 
• 1313513-39-1 2-bromo-5-chloro-4-(hydroxymethyl)benzoic acid 
• 1313513-45-9 C₁₇H₂₆BrClO₃Si 
• 1313513-46-0 (2-bromo-5-chloro-4-((triisopropylsilyloxy)methyl)phenyl)methanol 
• 1313513-44-8 (4-(allyloxymethyl)-5-bromo-2-chlorobenzyloxy)triisopropylsilane 
• 1313513-47-1 2-(4-(allyloxymethyl)-2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)phenyl)acetic acid 
• 1313513-48-2 2-(4-(allyloxymethyl)-2-chloro-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)-tetrahydro-2H-pyran-2-yl)benzyl)-5-(furan-2-yl)thiazole 
• 1313513-49-3 (2S,3R,4R,5S,6R)-2-(4-chloro-5-((5-(furan-2-yl)thiazol-2-yl)methyl)-2-(hydroxymethyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1313513-53-9 (2S,3R,4R,5S,6R)-2-(2-(allyloxymethyl)-4-chloro-5-((5-(furan-2-yl)thiazol-2-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1313513-50-6 (2S,3R,4R,5S,6R)-2-(4-chloro-5-((5-(furan-3-yl)thiazol-2-yl)methyl)-2-(hydroxymethyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1313513-54-0 (2S,3R,4R,5S,6R)-2-(2-(allyloxymethyl)-4-chloro-5-((5-(furan-3-yl)thiazol-2-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 
• 1313513-51-7 (2S,3R,4R,5S,6R)-2-(4-chloro-2-(hydroxymethyl)-5-((5-(thiophen-2-yl)thiazol-2-yl)methyl)phenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS

The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X); wherein Y', X', B', R1', R2', R3', R5', R6', R7', and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.

A new and improved process for C-aryl glucoside SGLT2 inhibitors

A practical and scalable synthesis of C-glycosides identified as highly potent sodium-dependent glucose transporter 2 (SGLT2) inhibitors is described. Highlights of the synthetic process are a concise, ten-step synthesis of a structurally complex active pharmaceutical ingredient from a known intermediate via a selective and quantitative addition of an aryl species to the Weinreb amide, and the isomers of undesired ortho-products were avoided during the preparation. The chemistry developed has been applied to prepare SGLT2 inhibitors without recourse to chromatography.

Improved preparation of (1S,3′R,4′S,5′S,6′R)-5- chloro-6-[(4-ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro- 6′-(hydroxymethyl)-spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′, 4′,5′-triol

A convenient approach for the preparation of (1S,3′R,4′S, 5′S,6′R)-5-chloro-6-[(4-ethylphenyl)methyl]-3′,4′, 5′,6′-tetrahydro-6′-(hydroxymethyl)-spiro[isobenzofuran-1(3H), 2′-[2H]pyran]-3′,4′,5′-triol is developed. The targeted compound was synthesized from 2-bromo-4-methylbenzoic acid in nine steps and the isomers of undesired ortho-products were avoided during the preparation.

Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof

The present invention relates to new pyrano[3,2-c]benzopyran-6(2H)-one derivatives that act as SGLT2 inhibitors, which makes them promising candidates for the treatment of diabetes and other diseases and conditions mediated by SGLT2. These new drugs also exhibit platelet aggregation inhibitory activity which makes them promising candidates in the treatment and/or prevention of prothrombotic conditions. The invention also relates to the use of such pyrano[3,2-c]benzopyran-6(2H)-one derivatives in the treatment or prevention of the diabetes and other disorders and conditions mediated by SGLT2, as a single active ingredient or in combination with another antidiabetic agent or a drug for the treatment of hypertension, chronic heart failure or atherosclerosis, and pharmaceutical compositions comprising said new pyrano[3,2-c]benzopyran-6(2H)-one derivatives.

PYRANO[3,2-c][2]BENZOPYRAN-6(2H)-ONE DERIVATIVES AND USES THEREOF

The present invention relates to new pyrano[3,2-c][2]benzopyran-6(2H)-one derivatives that act as SGLT2 inhibitors, which makes them promising candidates for the treatment of diabetes and other diseases and conditions mediated by SGLT2. These new drugs also exhibit platelet aggregation inhibitory activity which makes them promising candidates in the treatment and/or prevention of prothrombotic conditions. The invention also relates to the use of such pyrano[3,2-c][2]benzopyran-6(2W)-one derivatives in the treatment or prevention of the diabetes and other disorders and conditions mediated by SGLT2, as a single active ingredient or in combination with another antidiabetic agent or a drug for the treatment of hypertension, chronic heart failure or atherosclerosis, and pharmaceutical compositions comprising said new pyrano[3,2-c][2]benzopyran-6(2H)-one derivatives.

BORON-CONTAINING SMALL MOLECULES

This invention provides novel compounds, methods of using the compounds, and pharmaceutical compositions containing the compounds.

THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors

In order to investigate SAR regarding proximal phenyl ring in novel C-aryl glucoside SGLT2 inhibitors containing a thiazole motif, a series of chemical modifications on proximal phenyl ring was conducted. During a series of lead optimization efforts, orth

Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

(Chemical Equation Presented) Sodium glucose co-transporter 2 (SGLT2) is an emerging target for the treatment of type 2 diabetes mellitus (DM2). Here, the synthesis and preliminary biological evaluation of a series of potent, selective SGLT2 inhibitors, derived from a rigid spiro C-arylglucoside scaffold, is described.

O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

Two series of O-spiro C-aryl glucosides were synthesized and tested for inhibition of hSGLT1 and hSGLT2. 6′-O-Spiro C-aryl glucosides exhibited potent in vitro hSGLT2 inhibitory activity but 2′-O-spiro C-aryl glucosides showed no in vitro hSGLT2 inhibitory activity at a screening concentration of 1 μM.